Clinical Trial

DaTSCAN Imaging in Aging and Neurodegenerative Disease

Enrolling by Invitation Phase 4
View on ClinicalTrials.gov →
Summary
The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2011-10-12; most recent amendment 2026-03-06.
Status change: Recruiting → Enrolling by Invitation 2011-12-05
Status change: Not Yet Recruiting → Recruiting 2011-10-31
Trial Details
NCT Number NCT01453127
Lead Sponsor Mayo Clinic
Conditions Dementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior Disorder
Enrollment 500 participants
Start Date 2011-10
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-10